Rj Soiffer

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transpl
    Marcelo C Pasquini
    Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, USA
    J Clin Oncol 30:3194-201. 2012
  2. doi request reprint Immune modulation and chronic graft-versus-host disease
    Rj Soiffer
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, MA, USA
    Bone Marrow Transplant 42:S66-S69. 2008
  3. ncbi request reprint CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors
    R J Soiffer
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 19:1152-9. 2001
  4. pmc Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies
    Robert J Soiffer
    Dana Farber Cancer Institute, Boston, MA, USA
    Blood 117:6963-70. 2011
  5. ncbi request reprint Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion
    Robert J Soiffer
    Biol Blood Marrow Transplant 8:625-32. 2002
  6. ncbi request reprint Partial CD8+ T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host disease
    V T Ho
    Department of Medical Oncology, Biostatistics, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Bone Marrow Transplant 34:987-94. 2004
  7. ncbi request reprint CD8+ cell depletion of donor lymphocyte infusions using cd8 monoclonal antibody-coated high-density microparticles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: a pilot study
    E P Alyea
    Center for Hematologic Oncology, Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Bone Marrow Transplant 34:123-8. 2004
  8. ncbi request reprint Routine screening for psychosocial distress following hematopoietic stem cell transplantation
    S J Lee
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Bone Marrow Transplant 35:77-83. 2005
  9. pmc Preinfusion variables predict the predominant unit in the setting of reduced-intensity double cord blood transplantation
    R L Haspel
    Department of Pathology, Beth Israel Deaconess Medical Centre, Boston, MA 02115, USA
    Bone Marrow Transplant 41:523-9. 2008
  10. ncbi request reprint Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy
    A M Saito
    Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Bone Marrow Transplant 40:209-17. 2007

Collaborators

Detail Information

Publications75

  1. pmc Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transpl
    Marcelo C Pasquini
    Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, USA
    J Clin Oncol 30:3194-201. 2012
    ..However, concerns about relapse, graft rejection, and variability in technique have limited the widespread application of this approach...
  2. doi request reprint Immune modulation and chronic graft-versus-host disease
    Rj Soiffer
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, MA, USA
    Bone Marrow Transplant 42:S66-S69. 2008
    ..As efforts continue to devise strategies to treat and prevent chronic GVHD, it is important to acknowledge the link between cGVHD and freedom from relapse, at least for certain malignancies...
  3. ncbi request reprint CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors
    R J Soiffer
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 19:1152-9. 2001
    ..Herein, we report results in the first 48 recipients of unrelated marrow using CD6+ TCD as the sole form of GVHD prophylaxis...
  4. pmc Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies
    Robert J Soiffer
    Dana Farber Cancer Institute, Boston, MA, USA
    Blood 117:6963-70. 2011
    ..001). Corresponding probabilities of overall survival were 50%, 38%, and 46% (P = .008). These data suggest adopting a cautious approach to routine use of in vivo T-cell depletion with RIC regimens...
  5. ncbi request reprint Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion
    Robert J Soiffer
    Biol Blood Marrow Transplant 8:625-32. 2002
    ..Our results indicate that CD8 depletion reduces the incidence of GVHD associated with DLI without adversely affecting conversion to donor hematopoiesis or immunologic recovery...
  6. ncbi request reprint Partial CD8+ T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host disease
    V T Ho
    Department of Medical Oncology, Biostatistics, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Bone Marrow Transplant 34:987-94. 2004
    ..There was no correlation between CD8+ number and GVHD or survival. A 2-log depletion of CD8+ cells from PBSC is insufficient to prevent GVHD...
  7. ncbi request reprint CD8+ cell depletion of donor lymphocyte infusions using cd8 monoclonal antibody-coated high-density microparticles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: a pilot study
    E P Alyea
    Center for Hematologic Oncology, Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Bone Marrow Transplant 34:123-8. 2004
    ..The CD8-HDM Cell Separation System appears to be highly selective and effective in depleting CD8+ T cells from DLI apheresis products, and CD8-depleted DLI is capable of mediating a graft-versus-leukemia effect while minimizing GVHD...
  8. ncbi request reprint Routine screening for psychosocial distress following hematopoietic stem cell transplantation
    S J Lee
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Bone Marrow Transplant 35:77-83. 2005
    ..Pre-transplant distress appears to be highly predictive of distress post transplant and is a feasible marker to target screening and intervention programs...
  9. pmc Preinfusion variables predict the predominant unit in the setting of reduced-intensity double cord blood transplantation
    R L Haspel
    Department of Pathology, Beth Israel Deaconess Medical Centre, Boston, MA 02115, USA
    Bone Marrow Transplant 41:523-9. 2008
    ....
  10. ncbi request reprint Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy
    A M Saito
    Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Bone Marrow Transplant 40:209-17. 2007
    ..Our data suggest that substantially lower costs and fewer days of hospitalization within the first year after RICT procedures can be obtained with no compromise of long-term clinical outcomes compared to HDCT procedures...
  11. ncbi request reprint HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation
    V T Ho
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Bone Marrow Transplant 37:845-50. 2006
    ..0001). Cumulative relapse incidence was 35% in the HLA-C-mismatched and 55% in the 10/10-matched cohort, P=0.09. HLA-C mismatch is associated with inferior survival after URD NST...
  12. pmc Prolonged impairment of very late activating antigen-mediated T cell proliferation via the CD3 pathway after T cell-depleted allogeneic bone marrow transplantation
    K Sugita
    Division of Tumor Immunology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Clin Invest 94:481-8. 1994
    ..Our results imply that disturbance of VLA function could explain, at least in part, the persistent immunoincompetent state after allo-BMT and may be involved in susceptibility to opportunistic infections after allo-BMT...
  13. ncbi request reprint High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission
    A S Freedman
    Division of Hematologic Malignancies and Biostatistics, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 16:13-8. 1998
    ....
  14. ncbi request reprint Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant
    E P Alyea
    Divisions of Hematologic Malignancies and Biostatistics, Dana Farber Cancer Institute, Boston, MA, USA
    Blood 91:3671-80. 1998
    ....
  15. ncbi request reprint Recovery after stem-cell transplantation for hematologic diseases
    S J Lee
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 19:242-52. 2001
    ....
  16. ncbi request reprint Quantitation of T-cell neogenesis in vivo after allogeneic bone marrow transplantation in adults
    E P Hochberg
    Disease Center for Hematologic Oncology, Department of Adult Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston MA 02115, USA
    Blood 98:1116-21. 2001
    ..These studies demonstrate that T-cell neogenesis contributes to immune reconstitution in adult patients and suggest that thymic function can be manipulated in vivo. (Blood. 2001;98:1116-1121)..
  17. pmc Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia
    C J Wu
    Center for Hematologic Oncology, and Department of Biostatistical Science, Dana Farber Cancer Institute, and Department of Medicine, and Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Clin Invest 106:705-14. 2000
    ..The characterization of B cell-defined antigens may help identify clinically relevant targets of the GVL response in vivo...
  18. ncbi request reprint A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation
    J H Antin
    Department of Adult Oncology and Biostatistical Science, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Bone Marrow Transplant 29:373-7. 2002
    ..The use of IL-11 as GVHD prophylaxis in allogeneic transplantation cannot be recommended as administered in this trial...
  19. ncbi request reprint Altered tyrosine phosphorylation via the very late antigen (VLA)/beta1 integrin stimulation is associated with impaired T-cell signaling through VLA-4 after allogeneic bone marrow transplantation
    T Sato
    Division of Tumor Immunology, Dana Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Blood 90:4222-9. 1997
    ....
  20. ncbi request reprint Quality of life associated with acute and chronic graft-versus-host disease
    S J Lee
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Bone Marrow Transplant 38:305-10. 2006
    ..The adverse effects of acute GVHD are detectable with the TOI at 6 months post transplantation after which development of chronic GVHD is the most strongly correlated with worse QOL...
  21. pmc Multicenter validation study of a transplantation-specific cytogenetics grouping scheme for patients with myelodysplastic syndromes
    P Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Bone Marrow Transplant 45:877-85. 2010
    ..We propose that this SCT-specific cytogenetics grouping scheme be used for patients with MDS or AML arising from MDS who are considering or undergoing SCT...
  22. ncbi request reprint A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells
    E Zorn
    Center for Hematologic Oncology, Dana-Farber Cancer Institute, Department of Medicine, Brigham and Women Hospital, Harvard Medical School, Boston, MA 02115, USA
    Transplantation 71:1131-7. 2001
    ..Based on these findings, CD4+ T cells with BCR-ABL specificity do not appear to be mediators of the anti-leukemia response in vivo after donor lymphocyte infusion...
  23. ncbi request reprint Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation
    V T Ho
    Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 7:223-9. 2001
    ..Patients with pretransplantation FEV1 of < or = 80% appear to have a higher risk for SPCs...
  24. pmc CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia
    X F Yang
    Center for Hematologic Oncology, Dana Farber Cancer Institute, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 98:7492-7. 2001
    ..These findings suggest that CML66 may be immunogenic in a wide variety of malignancies and may be a target for antigen-specific immunotherapy...
  25. ncbi request reprint R24 anti-GD3 ganglioside antibody can induce costimulation and prevent the induction of alloantigen-specific T cell clonal anergy
    V A Boussiotis
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Eur J Immunol 26:2149-54. 1996
    ..Our data indicate that the membrane ganglioside GD3 structure recognized by R24 may play an important role in antigen-specific T cell clonal response...
  26. ncbi request reprint Post-transplant acute limbic encephalitis: clinical features and relationship to HHV6
    W W Seeley
    Department of Neurology, Brigham and Women s Hospital, Boston, MA, USA
    Neurology 69:156-65. 2007
    ..Clinical and laboratory features of the syndrome, however, have not been well characterized...
  27. pmc IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo
    Emmanuel Zorn
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 108:1571-9. 2006
    ..Our findings support the clinical evaluation of low-dose IL-2 to selectively modulate CD4+CD25+ Tregs and increase expression of FOXP3 in vivo...
  28. pmc Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation
    Corey Cutler
    Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 109:3108-14. 2007
    ..Differences between MRD and URD cohorts are not evident when effective GVHD prophylaxis is used...
  29. ncbi request reprint Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia
    Jennifer R Brown
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 12:1056-64. 2006
    ....
  30. ncbi request reprint Chronic myelogenous leukemia
    Susan O'Brien
    J Natl Compr Canc Netw 3:732-55. 2005
  31. ncbi request reprint Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome
    Edwin P Alyea
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 12:1047-55. 2006
    ..These results suggest that NST is a reasonable alternative for patients with advanced AML and MDS at high risk for complications after myeloablative transplantation...
  32. pmc Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation
    Philippe Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 109:4586-8. 2007
    ..They also suggest future prospective trials to examine the potential benefit of chelation therapy in this setting...
  33. ncbi request reprint High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials
    John Koreth
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 13:183-96. 2007
    ..01; 95% confidence interval, 1.64-5.50). Hence, evaluating alternative therapeutic options upfront may also be reasonable...
  34. pmc Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation
    Philippe Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 13:655-64. 2007
    ....
  35. doi request reprint Donor lymphocyte infusions for acute myeloid leukaemia
    Robert J Soiffer
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Best Pract Res Clin Haematol 21:455-66. 2008
    ....
  36. doi request reprint Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission
    Richard M Stone
    Department of Medical Oncology, Division of Hematologic Malignancies, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Am J Hematol 83:771-7. 2008
    ..This study supports further investigation of immunotherapy in the post-intensive chemotherapy setting in the management of patients with AML...
  37. pmc Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation
    Edwin P Alyea
    Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 14:920-6. 2008
    ....
  38. doi request reprint Recurrent acute promyelocytic leukemia presenting as a sacral nerve root mass
    Santosh Kesari
    Department of Neurology, Dana Farber Cancer Institute Brigham and Women s Hospital, Boston, MA, USA
    J Clin Oncol 26:3279-81. 2008
  39. doi request reprint Individual physician practice variation in hematopoietic cell transplantation
    Stephanie J Lee
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D5 290, Seattle, WA 98109, USA
    J Clin Oncol 26:2162-70. 2008
    ..Previous studies have evaluated practice variation in hematopoietic cell transplantation (HCT) among transplant centers and countries. There are no studies investigating individual physician practice variation in HCT...
  40. pmc Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome
    Philippe Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 14:418-25. 2008
    ..These results emphasize the importance of lymphoma histology for patients undergoing RIC SCT, as well as the lack of relevance of donor chimerism for outcome in this patient population...
  41. pmc Costs of allogeneic hematopoietic cell transplantation with high-dose regimens
    Akiko M Saito
    Division of Medical Oncology, Dana Farber Cancer Institute, and Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Biol Blood Marrow Transplant 14:197-207. 2008
    ..If no complications occurred, the mean cost within the first year was $79,222. These results provide cost estimates for complicated and uncomplicated HDCT procedures, as well as costs for management of specific transplant complications...
  42. pmc A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation
    Philippe Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 14:28-35. 2008
    ....
  43. pmc High levels of B-cell activating factor in patients with active chronic graft-versus-host disease
    Stefanie Sarantopoulos
    Division of Hematologic Malignancies and Department of Medical Oncolog, Dana Farber Cancer Institute and Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 13:6107-14. 2007
    ..Thus, we tested whether BAFF correlated with chronic GVHD disease activity and time of onset after allogeneic hematopoietic stem cell transplantation (HSCT)...
  44. pmc Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis
    Francisco M Marty
    Division of Infectious Diseases, Boston, MA 02115, USA
    Blood 110:490-500. 2007
    ..66; P = .14 and P = .35, respectively). The protective effect of sirolimus-containing GVHD prophylaxis regimens on CMV reactivation should be confirmed in randomized trials...
  45. pmc Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia
    John G Gribben
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Blood 106:4389-96. 2005
    ..From these findings we have altered our approach for patients with high-risk CLL and are currently exploring the role of related and unrelated allogeneic SCT following reduced-intensity conditioning regimens...
  46. ncbi request reprint Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma
    Roberto Bellucci
    Center for Hematologic Oncology and Department of Biostatistics, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 99:4610-7. 2002
    ..05). These results provide evidence that prophylactic infusion of CD4(+) donor lymphocytes 6 months after BMT enhances reconstitution of donor T cells and conversion to donor hematopoiesis as well as promoting antitumor immunity...
  47. ncbi request reprint Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study
    Francisco M Marty
    Division of Infectious Diseases and Hematopoietic Stem Cell Transpalntation Service, Brigham and Women s Hospital and Dana Farber Cancer Instiute, Harvard Medical School, Boston, MA 02115, USA
    Blood 102:2768-76. 2003
    ..Pre-emptive systemic antifungal therapy against molds should be considered in patients who develop severe GVHD after HSCT if infliximab is used...
  48. ncbi request reprint Optimistic expectations and survival after hematopoietic stem cell transplantation
    Stephanie J Lee
    Department of Medical Oncology, and Center for Outcomes and Policy Research, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 9:389-96. 2003
    ..Our data suggest an association between more optimistic expectations and early survival following hematopoietic stem cell transplantation, but this association is not present by 6 months posttransplantation...
  49. ncbi request reprint Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation
    Martha Wadleigh
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 102:1578-82. 2003
    ..Three of 14 patients who received GO prior to SC transplantation died of VOD. We conclude that patients undergoing SC transplantation within a short interval from GO administration are at increased risk of developing VOD...
  50. ncbi request reprint Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation
    Joseph H Antin
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 102:1601-5. 2003
    ..This novel agent is worthy of further study in allogeneic transplantation...
  51. ncbi request reprint Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation
    Edwin P Alyea
    Biol Blood Marrow Transplant 8:601-7. 2002
    ..However, these adverse events do not lead to inferior probability of relapse-free survival because they are accompanied by a reduction in relapse rates...
  52. ncbi request reprint Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation
    Deborah C Molrine
    Massachusetts Biologic Laboratories, University of Massachusetts Medical School, Jamaica Plain, MA 02130, USA
    Blood 101:831-6. 2003
    ..A 3-dose schedule of PCV7 vaccine at 3, 6, and 12 months is immunogenic in these patients regardless of donor immunization...
  53. ncbi request reprint Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation
    Joseph H Antin
    Department of Medical Oncology and Biostatistical Science, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 100:3479-82. 2002
    ..We conclude that blockade of IL-1 using IL-1Ra during conditioning and 10 days immediately after transplantation is not sufficient to reduce GVHD or toxicity or to improve survival...
  54. ncbi request reprint A novel rapid single nucleotide polymorphism (SNP)-based method for assessment of hematopoietic chimerism after allogeneic stem cell transplantation
    Ephraim P Hochberg
    Center for Hematologic Oncology and the Department of Biostatistics, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 101:363-9. 2003
    ..SNP-based assessment of chimerism is a promising technique that will assist in the analysis of outcomes following transplantation...
  55. ncbi request reprint Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs
    Stephanie J Lee
    Department of Adult Oncology and Department of Biostatistical Science, Dana Farber Cancer Institute, and the Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Blood 100:2697-702. 2002
    ..As prospective, randomized studies comparing methods of GVHD prophylaxis are performed, assessment of quality of life and costs should be included to fully understand the overall impact of each intervention...
  56. ncbi request reprint Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation
    Thomas S Lin
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Transplantation 74:49-54. 2002
    ..We sought to determine the effect of prior donor and patient CMV exposure on the incidence of CMV infection after TCD allogeneic HSCT...
  57. ncbi request reprint Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells
    Emmanuel Zorn
    Center for Hematologic Oncology, Dana Farber Cancer Institute, and Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 8:2052-60. 2002
    ..In this situation however, the immune effector cells responsible for tumor rejection have not been identified. The goal of this study was to characterize these effector populations...
  58. pmc Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors
    David B Miklos
    Department of Medical Oncology and Biostatistical Science, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115
    Blood 103:353-9. 2004
    ..These studies demonstrate that the immune response to mHA includes the generation of specific antibodies and suggests that the serologic response to these antigens may also be useful in the identification of new mHAs...
  59. ncbi request reprint Graft-versus-host disease of the vulva and/or vagina: diagnosis and treatment
    Lisa B Spiryda
    Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women s Medical Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Biol Blood Marrow Transplant 9:760-5. 2003
    ..Vaginal GVHD can successfully be treated with topical cyclosporine when mild to moderate disease is present. Surgical lysis with topical cyclosporine is required when more severe disease ensues...
  60. ncbi request reprint Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease
    Daniel J DeAngelo
    Dana Farber Cancer Institute, Department of Adult Oncology, Boston, Massachusetts 02115, USA
    Clin Cancer Res 10:5065-71. 2004
    ..Recent reports indicate that imatinib mesylate (Gleevec) can induce remissions in these patients as well. Less is known about the extent and durability of these responses...
  61. ncbi request reprint Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age
    Edwin P Alyea
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Blood 105:1810-4. 2005
    ..052). Our experience suggests that, in patients over age 50, NST with fludarabine and low-dose busulfan leads to an overall outcome at least as good as that following myeloablative therapy...
  62. ncbi request reprint Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation
    Joseph H Antin
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Biol Blood Marrow Transplant 11:213-22. 2005
    ..Pneumococcal conjugate vaccine is immunogenic in autoHCT patients and may be an effective strategy to prevent invasive disease after transplantation...
  63. pmc Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease
    Emmanuel Zorn
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 106:2903-11. 2005
    ..These findings support the development of new strategies to increase the number of Tregs following allogeneic hematopoietic stem cell transplantation to prevent or correct cGVHD...
  64. ncbi request reprint Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial
    Stephanie J Lee
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 104:1559-64. 2004
    ..002). Both relapse- and GVHD-related mortality contributed to the increased mortality in the combination group. The combination of corticosteroids and daclizumab should not be used as initial therapy of acute GVHD...
  65. pmc Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission
    David B Miklos
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, M530, Boston, MA 02115, USA
    Blood 105:2973-8. 2005
    ..Antibody response to Y-chromosome encoded histocompatibility antigens (H-Y antigens) was also associated with maintenance of disease remission (P < .0001). B cells may provide a new target for immune intervention in chronic GVHD...
  66. ncbi request reprint Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
    Vincent T Ho
    Dana Farber Cancer Institute, 44 Binney St, D1B21, Boston, MA 02115, USA
    Blood 104:1224-6. 2004
    ..Eight of 24 patients (33%) are alive at 6.3 to 24.6 months (median, 7.2 months). Denileukin diftitox is tolerable and has promising activity in steroid-refractory acute GVHD...
  67. ncbi request reprint Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation
    Corey Cutler
    Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 10:328-36. 2004
    ..Mucositis was modest, engraftment was prompt, and transplant-related toxicity was modest. Methotrexate-free, sirolimus-based GVHD prophylactic regimens should be tested in randomized trials against the current standard of care...
  68. pmc Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation
    Emmanuel Zorn
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, M530, Boston, MA 02115, USA
    J Exp Med 199:1133-42. 2004
    ..The specificity for recipient male cells was mediated by the B cell response and not by donor T cells. This dual DBX/DBY antigen is the first mHA to be identified in the context of chronic GVHD...
  69. ncbi request reprint Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy
    Abba C Zubair
    Connell O Reilly Cell Manipulation Core Facility, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Transfusion 44:253-61. 2004
  70. ncbi request reprint Phase II study of paclitaxel and carboplatin for malignant melanoma
    F Stephen Hodi
    Adult Oncology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Am J Clin Oncol 25:283-6. 2002
    ..Comparisons with other treatment regimens and the search for additional active compounds against melanoma are needed...
  71. ncbi request reprint CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells
    Xiao Feng Yang
    Center for Hematologic Oncology, Dana Farber Cancer Institute, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 62:5517-22. 2002
    ..Moreover, given its expression and immunogenicity in a wide variety of malignancies, CML28 merits additional evaluation as a target for antigen-specific immunotherapy...
  72. ncbi request reprint Chronic myelogenous leukemia
    Susan O'Brien
    University of Texas M D Anderson Cancer Center, USA
    J Natl Compr Canc Netw 5:474-96. 2007
  73. pmc Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosis
    Roberto Bellucci
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 109:2001-7. 2007
    ..Interestingly, the epitope specificity of these PDC-E2 autoantibodies was distinctive, suggesting that the mechanisms leading to loss of tolerance in the transplantation patients are distinct from PBC...
  74. pmc Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
    F Stephen Hodi
    Department of Adult Oncology, Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 100:4712-7. 2003
    ..These findings suggest that CTLA-4 antibody blockade increases tumor immunity in some previously vaccinated cancer patients...
  75. ncbi request reprint Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity
    Gerald P Linette
    Division of Hematology Oncology, Department of Medicine, Massachusetts General Hospital, Boston, 02114, USA
    Clin Cancer Res 11:7692-9. 2005
    ..To determine the toxicity, maximal tolerated dose, and clinical and immunologic response to autologous dendritic cells pulsed with melanoma-associated antigen gp100-derived G280-9V peptide...